Shots:

• The P-II trial (MagnetisMM-3) evaluating elranatamab (76mg, qw on a 28-day cycle) as monotx. in 187 patients with r/r MM who have received 3 classes of prior therapies incl. a proteasome inhibitor, an immunomodulatory agent & anti-CD38 mAb
• As the data cut-off on Oct 2022, elranatamab achieved a high ORR (61%) with no prior BCMA-targeted treatment with 84% probability of maintaining a response, probability of PFS & OS was 63% & 70%, respectively @9mos. while a step-up priming dose regimen (12/32mg) mitigated the rate & severity of CRS (58%, all grade 1/2) and ICANS (3%)
• The results also showed early & deep responses with a manageable safety profile for elranatamab in heavily pretreated patients

Ref: Pfizer | Image: Pfizer